Clinical Research Directory

Browse clinical research sites, groups, and studies.

RECRUITING

NCT06288633

Cardioneuroablation for Bradyarrhythmia

Sponsor: Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health

View on ClinicalTrials.gov

Summary

This is a multicenter prospective randomized blind controlled trial with a sham procedure group of the efficacy and safety of cardioneuroablation as a method of treating symptomatic bradycardia without a permanent pacemaker implantation

Official title: Cardioneuroablation for Bradyarrhythmia (Sinus Node and Atrioventricular Node Dysfunction): a Sham-controlled Randomised Multicentre Trial

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

106

Start Date

2024-03-04

Completion Date

2027-02-01

Last Updated

2024-03-05

Healthy Volunteers

Conditions

Bradycardia Syncope Sick Sinus Syndrome

Interventions

PROCEDURE

Ganglionated plexi ablation

Through access in the femoral vein, a mapping or ablation-mapping catheter is inserted into the right atrium, and a three-dimensional reconstruction of the right atrium is performed using an electroanatomic mapping system. The inferior and superior vena cava, the coronary sinus are indicated. Then a transeptal puncture is performed using a transeptal introducer and a needle for transeptal puncture under fluoroscopic control. A three-dimensional reconstruction of the left atrium is performed using an electroanatomic mapping system. During or immediately after the creation of three-dimensional maps of both atria, areas of the typical concentration of ganglion plexuses (GP) are ablated using radiofrequency applications (30-50 Watts, 10-40 s each point). Ablated points are annotated on the three-dimensional map. GPs ablation zones are about 0.5 x 1.0 cm in size.

DIAGNOSTIC_TEST

Electrophysiological study

Through access in the femoral vein, a diagnostic catheter is inserted in the area of the coronary sinus under fluoroscopic control. The effective refractory period (ERP) of the atria will be measured according to the method adopted in clinical practice, namely: using a ten-pole diagnostic electrode installed in the coronary sinus, a series of eight electrical pulses with the same amplitude and frequency is applied to the atrial myocardium. Then the ninth pulse is applied with a gradual decrease in the time interval until the absence of an atrial myocardium response to the pulse is registered. The cycle of an additional, ninth pulse, in which the atrial myocardium did not respond to an electrical impulse, is considered an atrial ERP.

Inclusion Criteria: 1. Any of the following variants of bradyarrhythmia in patients aged 18-65 years: (1.1.) Symptomatic sinus bradycardia or bradycardia due to atrioventricular blockade, including transient. (1.2.) Severe asymptomatic sinus bradycardia with a rhythm frequency of \<30 beats/min. (1.3.) Transient atrioventricular block of II-III degree or permanent block of II degree. (1.4.) Repeated fainting or pre-fainting states with a proven association with bradycardia (without injury). (1.5.) Rhythm pauses \>6 seconds. In combination with the following two criteria: 2. Positive reaction to physical activity and/or atropine test: (2.1.) Increase in sinus rhythm frequency ≥25% or \>90 beats/min. (2.2.) The transition of atrioventricular blockade of the II-III degree to the 1st degree or complete normalization of atrioventricular conduction at the sinus rhythm. 3. Sinus rhythm at the time of switching on Exclusion Criteria: 1. Anamnesis of injury during syncopation due to bradycardia, except in the case when the patient refused to implant an electrocardiostimulator for his own reasons in writing; 2. Constant intake of antiarrhythmic drugs (for PVC, AF, etc.); 3. The presence of an implanted pacemaker, a heart contractility modulation device, a cardioverter defibrillator; 4. Drug-induced sinus bradycardia and/or atrioventricular block; 5. Bradycardia due to electrolyte imbalance (e.g. hyperkalemia); 6. Bradycardia due to hypothyroidism or other reversible conditions; 7. No reaction to the administration of atropine (up to a maximum dose of 0.2 mg / kg); 8. Proven association of bradyarrhythmia with episodes of apnea/hypopnea in obstructive sleep apnea syndrome; 9. Clinically significant coronary artery disease; 10. Postinfarction cardiosclerosis; 11. Hemodynamically significant congenital heart defects, including operated ones; 12. Stroke or transient ischemic attack \<3 months; 13. Open heart surgery in the anamnesis; 14. Catheter interventions on coronary arteries or for cardiac arrhythmias \<3 days; 15. Conditions after percutaneous coronary angioplasty \<3 months; 16. Anamnesis of stable ventricular tachycardia on the background of bradycardia; 17. Pregnancy or breastfeeding period

Locations (1)

Almazov National Medical Research Centre

Saint Petersburg, Russia